Brisbane, Australia-XING Genomic Services, a subsidiary of XING Technologies, is pleased to announce that they have received NATA accreditation effective from July 2021 to offer clinical cancer genetic testing using the Pillar Biosciences HRD (homologous recombination deficiency) assay. This test identifies cancer patients that have tumours with impaired DNA repair capability, making them more likely ...XING Genomic Services receives NATA accreditation for Pillar Biosciences HRD Gene Panel Enabling Cost-Effective PARPi-response Prediction Read More »The post XING Genomic Services receives NATA accreditation for Pillar Biosciences HRD Gene Panel Enabling Cost-Effective PARPi-response Prediction appeared first on Pillar Biosciences.
Pillar Biosciences is a Massachusetts-based biotechnology company that provides solutions such as cell-free DNA analysis, liquid biopsy and next-generation sequencing.